Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2013 | Original Paper

Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients

Authors: Christine Schröder, Karin Milde-Langosch, Florian Gebauer, Katharina Schmid, Volkmar Mueller, Ralph M. Wirtz, Catherine Meyer-Schwesinger, Hartmut Schlüter, Guido Sauter, Udo Schumacher

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2013

Abstract

Purpose

The ubiquitin C-terminal hydrolase L1 (UCH-L1) belongs to the family of deubiquitinating enzymes. It is overexpressed in various tumour entities and associated with metastases formation in some solid tumours. However, only limited information about its role in breast cancer is available. The aim of this study was to examine the UCH-L1 expression in primary breast cancer and to determine its relevance as a potential prognostic marker.

Methods

We investigated both UCH-L1 mRNA expression in microarray data from 182 primary mammary carcinomas and UCH-L1 protein expression using a tissue microarray containing samples from 1,622 breast cancer patients.

Results

With both methods, high UCH-L1 expression correlated significantly with negative oestrogen receptor and progesterone receptor status and advanced tumour stage. Moreover by Kaplan–Meier analysis, high UCH-L1 mRNA and protein expression correlated with a significantly shorter overall survival.

Conclusion

The data of our study suggest that high levels of UCH-L1 expression indicate a more aggressive tumour behaviour and might represent a potential target in breast cancer treatment.

Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, Kanai Y, Hirohashi S (2010) Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. Am J Clin Pathol 134(1):71–79. doi: 10.1309/AJCPRJP39MIDSGBH PubMedCrossRef

Doran JF, Jackson P, Kynoch PA, Thompson RJ (1983) Isolation of PGP 9.5, a new human neurone-specific protein detected by high-resolution two-dimensional electrophoresis. J Neurochem 40(6):1542–1547PubMedCrossRef

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19(5):403–410PubMedCrossRef

Fang Y, Fu D, Shen XZ (2010) The potential role of ubiquitin c-terminal hydrolases in oncogenesis. Biochim Biophys Acta 1:1–6. doi:10.1016/j.bbcan.2010.03.001

Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ (1996) Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 88(20):1456–1466PubMedCrossRef

Hayes DF, Ethier S, Lippman ME (2006) New guidelines for reporting of tumor marker studies in breast cancer research and treatment: REMARK. Breast Cancer Res Treat 100(2):237–238. doi:10.1007/s10549-006-9253-5 PubMedCrossRef

Hurst-Kennedy J, Chin LS, Li L (2012) Ubiquitin C-terminal hydrolase l1 in tumorigenesis. Biochem Res Int 2012:123706. doi: 10.1155/2012/123706

Hussain S, Foreman O, Perkins SL, Witzig TE, Miles RR, van Deursen J, Galardy PJ (2010) The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia 24(9):1641–1655. doi: 10.1038/leu.2010.138 PubMedCrossRef

Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Itesako T, Kawamoto K, Nishiyama K, Seki N, Nakagawa M (2008) CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol 180(1):343–351. doi:10.1016/j.juro.2008.02.044 PubMedCrossRef

Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Lee KJ (2009) Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 28(1):117–127. doi:10.1038/onc.2008.364 PubMedCrossRef

Larsen CN, Price JS, Wilkinson KD (1996) Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 35(21):6735–6744. doi:10.1021/bi960099f PubMedCrossRef

Larsen CN, Krantz BA, Wilkinson KD (1998) Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry 37(10):3358–3368. doi:10.1021/bi972274d PubMedCrossRef

Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I (2007) Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. Prostate 67(16):1761–1769. doi:10.1002/pros.20654 PubMedCrossRef

Liu X, Zeng B, Ma J, Wan C (2009) Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest 27(3):345–352. doi:10.1080/07357900802438577 PubMedCrossRef

Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim MS, Osada M, Mori M, Sidransky D (2005) PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 65(11):4963–4968. doi:10.1158/0008-5472.CAN-04-3923 PubMedCrossRef

Miyoshi Y, Nakayama S, Torikoshi Y, Tanaka S, Ishihara H, Taguchi T, Tamaki Y, Noguchi S (2006) High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci 97(6):523–529. doi:10.1111/j.1349-7006.2006.00202.x PubMedCrossRef

National Cancer Institute. Surveillance Epidermiology and End Results (2008) http://www.seer.cancer.gov

Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, Bernards R (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123(5):773–786. doi:10.1016/j.cell.2005.11.007 PubMedCrossRef

Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, Ushijima T (2006) Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 119(6):1338–1344. doi:10.1002/ijc.22025 PubMedCrossRef

Ootsuka S, Asami S, Sasaki T, Yoshida Y, Nemoto N, Shichino H, Chin M, Mugishima H, Suzuki T (2008) Useful markers for detecting minimal residual disease in cases of neuroblastoma. Biol Pharm Bull 31(6):1071–1074PubMedCrossRef

Orr KS, Shi Z, Brown WM, O’Hagan KA, Lappin TR, Maxwell P, Percy MJ (2011) Potential prognostic marker ubiquitin carboxyl-terminal hydrolase-L1 does not predict patient survival in non-small cell lung carcinoma. J Exp Clin Cancer Res 30:79. doi: 10.1186/1756-9966-30-79

Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ, Sakurai M, Harada T, Hara Y, Kimura I, Chiba S, Namikawa K, Kiyama H, Noda M, Aoki S, Wada K (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12(16):1945–1958PubMedCrossRef

Otsuki T, Yata K, Takata-Tomokuni A, Hyodoh F, Miura Y, Sakaguchi H, Hatayama T, Hatada S, Tsujioka T, Sato Y, Murakami H, Sadahira Y, Sugihara T (2004) Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. Br J Haematol 127(3):292–298. doi:10.1111/j.1365-2141.2004.05205.x PubMedCrossRef

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140PubMed

Rosas SL, Koch W, da Costa Carvalho MG, Wu L, Califano J, Westra W, Jen J, Sidransky D (2001) Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 61(3):939–942PubMed

Ruiz C, Seibt S, Al Kuraya K, Siraj AK, Mirlacher M, Schraml P, Maurer R, Spichtin H, Torhorst J, Popovska S, Simon R, Sauter G (2006) Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer 118(9):2190–2194. doi:10.1002/ijc.21581 PubMedCrossRef

Schumacher U, Mitchell BS, Kaiserling E (1994) The neuronal marker protein gene product 9.5 (PGP 9.5) is phenotypically expressed in human breast epithelium, in milk, and in benign and malignant breast tumors. DNA Cell Biol 13(8):839–843PubMedCrossRef

Seliger B, Fedorushchenko A, Brenner W, Ackermann A, Atkins D, Hanash S, Lichtenfels R (2007) Ubiquitin COOH-terminal hydrolase 1: a biomarker of renal cell carcinoma associated with enhanced tumor cell proliferation and migration. Clin Cancer Res 13(1):27–37. doi:10.1158/1078-0432.CCR-06-0824 PubMedCrossRef

Simon R, Mirlacher M, Sauter G (2004) Tissue microarrays. Biotechniques 36(1):98–105PubMed

Tezel E, Hibi K, Nagasaka T, Nakao A (2000) PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 6(12):4764–4767PubMed

Thompson RJ, Doran JF, Jackson P, Dhillon AP, Rode J (1983) PGP 9.5–a new marker for vertebrate neurons and neuroendocrine cells. Brain Res 278(1–2):224–228PubMedCrossRef

Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, Sidransky D (2008) The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 123(4):753–759. doi:10.1002/ijc.23354 PubMedCrossRef

Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J (1989) The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246(4930):670–673PubMedCrossRef

Wilkinson KD, Deshpande S, Larsen CN (1992) Comparisons of neuronal (PGP 9.5) and non-neuronal ubiquitin C-terminal hydrolases. Biochem Soc Trans 20(3):631–637PubMed

Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, Inoue H, Mori M, Sidransky D (2006) PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 66(7):3921–3927. doi:10.1158/0008-5472.CAN-05-1511 PubMedCrossRef

Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, Ito K, Akiyama S, Nagasaka T, Nakao A (2002) PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 8(1):192–195PubMed

Title: Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients
Authors: Christine Schröder
Karin Milde-Langosch
Florian Gebauer
Katharina Schmid
Volkmar Mueller
Ralph M. Wirtz
Catherine Meyer-Schwesinger
Hartmut Schlüter
Guido Sauter
Udo Schumacher
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2013
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-013-1496-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2013

Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer

Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma

Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels

Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective

MicroRNAs targeting EGFR signalling pathway in colorectal cancer

TIS21/BTG2 inhibits invadopodia formation by downregulating reactive oxygen species level in MDA-MB-231 cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials